Japan Study To Investigate New Nivolumab Combo
This article was originally published in PharmAsia News
The efficacy promise presented by combinations of new cancer immunotherapies was a major factor behind Pfizer's recent major alliance with Merck Kgaa. On a smaller scale, it is now the driving force behind a planned clinical study in Japan with a first-in-class PD-1 inhibitor.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.